Bulut I, et al. - In this study including 36 asthmatic subjects and 36 healthy controls, researchers assessed the impacts of omalizumab on serum pregnancy-associated plasma protein-A (PAPP-A), insulin-like growth factor binding protein-4 (IGFBP-4), and insulin-like growth factor (IGF)-1 levels in those with severe allergic asthma. Patients with severe asthma were examined for serum PAPP-A levels, serum levels of IGF-1, IGFBP-4, both before therapy (baseline) and after six months of omalizumab therapy. Asthmatics had significantly higher serum PAPP-A and IGFB-4 levels than controls. However, both asthmatic subjects and control subjects had similar serum IGF-I levels. Serum PAPP-A, IGF-I, and IGFB4 levels in asthma subjects showed significant reduction after 6-month omalizumab treatment. Overall, in patients with severe asthma receiving omalizumab, PAPP-A level was suggested to have utility as a biomarker for predicting airway remodeling and may also reflect the response to treatment.